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risk stratification of hypertrophic cardiomyopathy (HC). Cardiac Magnetic 
Resonance (CMR) imaging is increasingly being used in the assessment of 
HC however, little is known about the relationship between wall thickness 
measurements made by the 2 modalities. We sought to compare measurements 
made with echocardiography and CMR and to assess the impact of any 
differences on risk stratification using the current European Society of 
Cardiology (ESC) guidelines. Maximum LV wall thickness measurements were 
recorded on 50 consecutive patients with HC. 69% of LV wall thickness 
measurements were recorded with echocardiography, compared to 69% from 
CMR (p<0.001). There was poor agreement on the location of maximum LV 
wall thickness; weighted-Cohen's κ 0.14 (p 0.036) and maximum LV wall 
thicknesses were systematically higher with echocardiography than with 
CMR (mean 19.1±0.4mm vs 16.5±0.3mm, p<0.01 respectively), Bland-Altman 
bias 2.6mm (95% confidence interval -9.8 to 4.6). Inter-observer 
variability was lower for CMR (R2 0.67 echocardiography, R2 0.93 CMR). 
The mean difference in 5-year sudden cardiac death (SCD) risk between 
echocardiography and CMR was 0.49±0.45% (p=0.37). When classifying 
patients (low, intermediate or high risk), 6 patients were reclassified 
when CMR was used instead of echocardiography to assess maximum LV wall 
thickness. These findings suggest that CMR measures of maximum LV wall 
thickness can be cautiously used in the current ESC risk score 
calculations, although it is preferable to use wall measurements recorded 
by echocardiography. 
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Abstract  
Echocardiography-derived measurements of maximum left ventricular (LV) wall thickness 
are important for both the diagnosis and risk stratification of hypertrophic cardiomyopathy 
(HC). Cardiac Magnetic Resonance (CMR) imaging is increasingly being used in the 
assessment of HC however, little is known about the relationship between wall thickness 
measurements made by the 2 modalities. We sought to compare measurements made with 
echocardiography and CMR and to assess the impact of any differences on risk stratification 
using the current European Society of Cardiology (ESC) guidelines. Maximum LV wall 
thickness measurements were recorded on 50 consecutive patients with HC. 69% of LV wall 
thickness measurements were recorded with echocardiography, compared to 69% from 
CMR (p<0.001). There was poor agreement on the location of maximum LV wall thickness; 
weighted-Cohen’s κ 0.14 (p 0.036) and maximum LV wall thicknesses were systematically 
higher with echocardiography than with CMR (mean 19.1±0.4mm vs 16.5±0.3mm, p<0.01 
respectively), Bland-Altman bias 2.6mm (95% confidence interval -9.8 to 4.6). Inter-observer 
variability was lower for CMR (R2 0.67 echocardiography, R2 0.93 CMR). The mean 
difference in 5-year sudden cardiac death (SCD) risk between echocardiography and CMR 
was 0.49±0.45% (p=0.37). When classifying patients (low, intermediate or high risk), 6 
patients were reclassified when CMR was used instead of echocardiography to assess 
maximum LV wall thickness. These findings suggest that CMR measures of maximum LV 
wall thickness can be cautiously used in the current ESC risk score calculations, although it 
is preferable to use wall measurements recorded by echocardiography.  
Keywords Hypertrophic Cardiomyopathy (HC), sudden cardiac death (SCD), Maximum Left 
Ventricular wall thickness, Cardiovascular Magnetic Resonance (CMR) 
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Hypertrophic cardiomyopathy (HC) is defined by the presence of increased left ventricular 
(LV) wall thickness, not solely explained by abnormal loading conditions 1. HC is the most 
common cause of sudden cardiac death (SCD) in those under the age of 35 years old 2,3. 
However, only a small subset of patients are at increased risk and identifying these patients 
remains challenging. Maximum LV wall thickness as assessed by 2D-echocardiography has 
been found to be of prognostic value in risk stratification 2,4,5. Recently a clinical risk 
prediction model has been developed incorporating echocardiography-derived 
measurements of maximum LV wall thickness 6 and one of the major strengths of this 
prediction model is that maximum LV wall thickness is assessed in a continuous method, 
rather than dichotomously as previously advocated 2,4,7,8. Echocardiography and CMR are 
both commonly used to evaluate patients with HC and in clinical practice LV wall thickness 
measurements are frequently used interchangeably. However, echocardiography may 
overestimate LV wall thickness when compared to CMR 9 or underappreciate hypertrophy in 
some settings. The magnitude of any differences in measurements between the two 
modalities and their impact on risk stratification using the European Society of Cardiology 
(ESC) risk score is unknown. The main objective of this study was to assess the presence 
and extent of any systematic difference between LV wall thickness measurements by 
echocardiography and CMR and to determine the effect of using CMR-derived LV wall 
thickness measurements on ESC SCD risk score. 
 
Methods 
Maximum LV wall thickness measurements were recorded on 50 consecutive 
patients with HC referred for echocardiography and CMR at our institution between 2014 
and 2015. Patients with implantable cardioverter defibrillators (ICDs), pacemakers or other 
contraindications to CMR were excluded. Written informed consent was obtained from all 
patients and the National Health Service ()NHS Health Research Authority ethics committee 
(REC Study number 15/NS/0030) approved the study.  
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Each patient underwent transthoracic echocardiography according to the protocol set 
by the British Society Echocardiography (BSE) guidelines by a trained sonographer10. 
Images were stored digitally and analyzed offline by an experienced BSE-accredited 
clinician blinded to the CMR measurements. Standard measures of cardiac dimensions were 
determined from the mean of 3 cardiac cycles. The end-diastolic thickness of the anterior, 
septal, inferior and lateral segments were recorded at the basal, mid and apical parasternal 
short-axis levels 11. Twenty-five patients were analysed by two clinicians to assess inter-
observer variability.  
All patients underwent CMR imaging using either a 1.5-T or 3.0-T scanners (Philips 
Achieva, Philips Healthcare, Best, Netherlands) according to standard acquisition protocols 
set by the Society for Cardiovascular Magnetic Resonance (SCMR) 12. ECG-gated, breath-
hold steady-state free precession cine images were acquired in both the long-axis and the 
short-axis planes from the apex to the base of the left ventricle, with slice thicknesses of 8 
mm. Only short axis stacks that were on axis with the mitral valve annulus were used for 
analysis. Images were analyzed offline using dedicated software (CVI42, Circle 
Cardiovascular Imaging Inc, Calgary, Alberta, Canada) by an experienced CMR clinician, 
blinded to the echo results. The same segments were recorded on CMR as described above 
on echocardiography, and similarly, 25 patients were analysed by two clinicians to assess 
inter-observer variability.  
Hospital databases and records were used to confirm the other risk factors (history of 
syncope, family history SCD, LV outflow tract gradient, age, non-sustained ventricular 
tachycardia (NSVT), left atrial size) identified in the ESC SCD risk score calculation.  
Categorical data are presented as frequencies and percentages. Comparisons 
between CMR and echocardiography group were made using McNemar’s test. Continuous 
data were assessed for normality using the Shapiro-Wilks test. Data are presented as mean 
± standard deviation (SD) or as median (interquartile range) depending on normality and 
were compared using Student’s t-test or the Wilcoxon signed rank method as appropriate. 
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Classification agreement was assessed using weighted-Cohen’s κ. Comparisons of wall-
thickness measurements made by the two modalities together with interobserver variability 
assessments were made using the methods of Bland and Altman 13. Interobserver variability 
was also quantified using the Pearson correlation. Differences in risk classification between 
the two modalities were evaluated using the Stuart-Maxwell test for marginal homogeneity. 
For all statistical analysis, two-tailed values of p<0.05 were considered significant.  
 
Results 
Patients’ demographics are summarized in Table 1. Only 12 patients had all the 
twelve AHA segments recorded using echocardiography. For direct comparison only 
matched data was used (Table 2). Figure 1 shows echo and CMR images from the same 
patient illustrating how challenging it can be to measure LV wall thicknesses accurately with 
echocardiography due to poor endocardial definition. There was poor agreement on the 
location of maximum LV wall thickness using AHA segments with weighted-Cohen’s κ 
calculated at 0.14 (p 0.036), table 3.  
Overall, the 50 measures of myocardial maximum LV wall thickness were higher on 
echocardiography than CMR (mean 19.1±0.4mm vs 16.5±0.3mm, p<0.01 respectively, 
Figure 2). A Bland Altman plot was used, demonstrating a systematic difference of 
2.6±3.7mm (95% confidence interval -9.8 to 4.6), Figure 3. The interclass correlation was 
0.51 (95% confidence intervals 0.3-0.7).  
There was less variation in inter-observer variability with CMR than 
echocardiography. R was calculated as 0.82 for the echocardiography measurements of LV 
wall thickness, with R2 0.67 compared to R 0.96 for CMR measurements of LV wall 
thickness, with R2 0.93. A Bland Altman plot has been used to show these differences in 
inter-observer variability for echocardiography and CMR, Figures 4A and 4B. 
The SCD risk score was calculated for all 50 patients using both the maximum LV 
wall thicknesses from echocardiography and CMR; patients were classified as low risk of 
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SCD (5 year risk under 4%) intermediate risk (5 year risk 4-6%) or high risk (5 year risk over 
6%). There was no statistically significant difference in 5-year SCD risk score between 
echocardiography and CMR (0.47±0.4% (p=0.37). However, the maximum LV wall 
measurements from CMR resulted in 6 patients allocated to lower risk categories: with 
echocardiography, 2 patients were classified as high risk, 8 as intermediate and 40 as low 
risk whereas, with CMR, 1 patient was classified as high risk 5 intermediate and 44 patients 
as low risk, Figure 5. The two patients with maximum LV wall thickness on CMR located in 
segments not measured by echocardiography were classified as low risk with both 
echocardiography and CMR risk calculations.  
 
Discussion 
In this cohort of patients with HC, we found that the disparity of 2.6mm between 
echocardiography and CMR measurements of maximum LV wall thickness did not translate 
to a statistical difference in the current SCD risk scores, although did result in fewer patients 
being identified as high risk. 
This is in contrast to Rickers et al, who showed no significant difference in LV wall 
thickness between echocardiography and CMR in 48 patients with HC, although the authors 
did not perform a detailed comparison between the imaging modalities 14. Previous work has 
shown greater discrepancy in LV wall thickness measurements with echocardiography, with 
increasing distance from the transducer 15.  
There are many possible reasons for the discrepancy between the two imaging 
modalities. CMR has better spatial resolution in patients with suboptimal echocardiography 
images and in the apical and anterolateral segments 16. Another possible reason for 
discrepancy is that the echocardiogram images recorded were analysed retrospectively and 
so we had to analyse the images that the sonographers have saved. In comparison, when 
we analysed the CMR we were able to choose the basal, mid and apical slices from the 
short axis stack, since the images were acquired with full LV coverage and without obliquity. 
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Moreover, with CMR the ventricular slices could always be acquired parallel to the mitral 
valve annulus, whereas with echocardiography the same degree of standardization was not 
possible. CMR has previously been shown to have superior inter-observer variability due to 
improved spatial resolution 9, and this was confirmed in this study. 
From the echocardiographic data recorded it was not possible to record all LV wall 
thicknesses, particularly in the apical slices. This is important, as one of the benefits of CMR 
is the improved differentiation of the LV wall compared to the papillary muscles and 
surrounding trabeculation. Two patients had apical hypertrophy on CMR but no 
echocardiographic apical measurements, although had a diagnosis of HC made from the 
other segments on echocardiography. They were both eventually categorized at low risk. 
Apart from previous sustained ventricular tachycardia, no one risk factor can be used 
in isolation to identify patients at high risk of SCD. HC remains one of the most frequent 
cause of SCD in the young, and in athletes under 35 years old in countries without 
systematic sports screening programmes 17. The greatest number of SCD events occur in 
patients with LV wall thickness between 20 and 25mm6. On its own, a 2.6mm difference in 
LV wall thickness does not change the ESC recommendation or change the patient’s 
individual risk, but the addition of more risk factors increases the chance of SCD.  
The importance of echocardiography is clear in establishing the risk of sudden 
cardiac death, not least as half of the pre-specified predictor variables are assessed on 
echocardiography (maximum LV wall thickness, LA diameter, LV outflow tract obstruction 
and fractional shortening – although the latter was not included in the final risk model). In 
addition, most clinicians have better access to echocardiography than CMR. Despite this, 
CMR has a clear role in assessing if fibrosis is present and its extent, as well as confirming 
LV volumes and wall mass. In 2014, Elliott et al recommended that CMR should be 
considered in patients with HC at their baseline assessment if local resources and expertise 
permit 18. A year later, Cardim et al, proposed a multimodality imaging approach to patients 
with HC 19. The authors recommended echocardiography as the first line imaging modality 
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for family screening and for pre clinical diagnosis, but for CMR when image quality is 
suboptimal, in high-risk families when echocardiography is non-diagnostic and when a ‘more 
complete SCD risk assessment’ is required. The suggestion is that these LV wall 
measurements can be used interchangeably, although there is no previous evidence 
supporting this. Our study in 50 patients is the first to show a statistically significant 
difference between echocardiography and CMR maximum LV wall measurements. These 
differences did not translate into a statistically significant difference in SCD risk scores, 
although using CMR did result in 6 patients being reclassified into lower risk groups. As LV 
wall thickness is a continuous variable in the risk predictor model, we recommend that 
echocardiographic measurements be used if available and acceptable image quality, and 
CMR measurements can be used cautiously if appropriate. Studies such as the Hypertrophic 
CardioMyopathy Registry (HCMR) is currently recruiting, will further our understanding in this 
field, as the aim is to establish novel predictors of outcome in HC using CMR. 
The limitations of this study are the small numbers of patients and that not all 
measurements were recorded using echocardiography. In addition, the left atrial dimensions 
were measured from echocardiography, but these might have changed when using CMR 
measurements, which might have further changed the ESC SCD score. Clinically in our 
institution, echocardiography is performed by a sonographer who measures LV wall 
thickness and acquires images for further reference; clinicians will verify or repeat the LV 
wall thickness measurements. This is in comparison to CMR where all the data is saved and 
is analysed and reported twice by at least two clinicians (although for this study, 
echocardiography measurements were measured by clinicians). It is likely that this is a 
similar set up to other hospitals in the United Kingdom, but these results may not applicable 
worldwide due to differing availability of CMR and differing levels of experience and 
expertise. Moreover, this study was not designed to address follow up, as current studies 
such as HCMR are actively recruiting and designed to address these outcomes.  
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Figure Legends 
Figure 1: Cardiac Magnetic Resonance images (A) and echocardiography (B) from the same 
patient showing difficulties visualizing accurately left ventricular myocardium 
Figure 2: Maximum left ventricular wall thickness (mm) measurements using 
echocardiography and Cardiac Magnetic Resonance  
Figure 3: Bland Altman Plot to show difference between echocardiography and Cardiac 
Magnetic Resonance for maximum left ventricular wall thickness measurements 
Figure 4: Reproducibility of maximum left ventricular wall thickness measurements. Bland 
Altman Plot for LV wall thickness measurements measured by Cardiac Magnetic Resonance 
(4A) and echocardiography (4B)  
Figure 5: Difference in Sudden Cardiac Death risk stratification classification using 
echocardiography and Cardiac Magnetic Resonance 
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Table 1: Patients demographics (n=50) 
Variable                                                           Patients 
 
Average age ± SD (years) 57 ± 16 
Female                                                            13 (26%) 
Ethnicity: White                                                               34 (68%) 
Ethnicity: Asian                                                                5 (10%) 
Ethnicity: Black  11 (22%) 
Family history sudden cardiac death (SCD) 7 (14%) 
Unexplained syncope                                      4 (8%) 
Non Sustained Ventricular Tachycardia  (NSVT)        13 (26%) 
 
Table 1
Table 2: Left Ventricular (LV) wall thickness measurements from Cardiac Magnetic 
Resonance (CMR) and echocardiography. Measurements of LV in mm ± SD 
Location of 
wall 
thickness 
LV wall 
thickness 
CMR  
LV wall thickness 
echocardiography  
P value Number of 
Patients recorded 
CMR 
 
Number of 
Patients recorded 
echocardiography 
Total number of segments 600 (100%) 414 (69%) 
 
Basal 
anterior 
10.0 ± 4 15.4 ± 6 <0.0001 50 (100%) 44 (88%) 
Basal septal 14.9 ± 4 16.5 ± 4 0.03 50 (100%)  48 (96%) 
Basal 
inferior 
8.2 ± 3 14.3 ± 4 <0.0001 50 (100%) 46 (92%) 
Basal lateral 7.7 ± 3 12.1 ± 3 <0.0001 50 (100%) 45 (90%) 
Mid anterior 9.6 ± 4 14.9 ± 5 <0.0001 50 (100%) 40 (80%) 
Mid septal 13.5 ± 4 16.9 ± 5 0.0007 50 (100%) 42 (84%) 
Mid inferior 10.1 ± 3 14.1 ± 4 <0.0001 50 (100%) 41 (82%) 
Mid lateral 8.1 ± 3 12.2 ± 3 <0.0001 50 (100%) 39 (78%) 
Apical 
anterior 
9.0 ± 4 14.4 ± 5 <0.0001 50 (100%) 17 (34%) 
Apical 
septal 
8.4 ± 3 17.0 ± 6 <0.0001 50 (100%) 18 (36%) 
Apical 
inferior 
8.5 ± 3 13.2 ± 4 <0.0001 50 (100%) 17 (34%) 
Apical 
lateral 
8.9 ± 4 12.4 ± 3 0.0025 50 (100%) 17 (34%) 
 
Table 2
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Table 3: Number of patients (%) with maximum Left Ventricle (LV) wall thickness location by 
Cardiac Magnetic Resonance (CMR) and echocardiography. 
 
Location of Wall Thickness By CMR By echocardiography 
 
Basal anterior segment 4 (8%) 8 (16%) 
Basal septal segment 25 (50%) 11 (22%) 
Basal anterior/septal segments 29 (58%) 19 (38%) 
Basal inferior segment 1 (2%) 3 (6%) 
Basal lateral segment - 1 (2%) 
Mid anterior segment 2 (4%) 5 (10%) 
Mid septal segment 14 (28%) 9 (18%) 
Mid anterior/septal segments 16 (32%) 14 (28%) 
Mid inferior segment - 3 (6%) 
Mid lateral segment - 3 (6%) 
Apical anterior segment 2 (4%) 3 (6)% 
Apical septal segment 1 (2%) 4 (8%) 
Apical anterior/septal segments 3 (6%) 7 (14%) 
Apical inferior segment 1 (2%) 1 (2%) 
Apical lateral segment - - 
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